Skip to main content
Premium Trial:

Request an Annual Quote

Fosun Diagnostics to Market Miacom's Molecular Beacon Assays in Asia

NEW YORK (GenomeWeb) — Miacom Diagnostics and Fosun Diagnostics said today that they have partnered to market Miacom's molecular beacon-based diagnostic assays to the Chinese and broader Asian markets.

Under the agreement, Shanghai-based Fosun, the diagnostic division of Shanghai Fosun Pharmaceutical, will market Dusseldorf, Germany-based Miacom's proprietary multiplex assays for the detection of sepsis- and pneumonia-related pathogens.

Miacom's assays enable the identification of a wide variety of pathogens using molecular beacons and fluorescence in situ hybridization, according to its website. The company also said its tests use a proprietary sample-handling method, and that its assays can identify and differentiate various bacteria in 30 minutes.

Having Fosun Diagnostics as a partner "makes widespread distribution of our products in the Asian market feasible," Miacom CEO Mirko Stange said in a statement. "We believe that this partnership will further strengthen our position in other markets, as well."

Fosun Diagnostics is planning to build a US Food and Drug Administration-compliant, large-scale production facility that will dramatically reduce the production costs of Miacom's products and help the company move into the European and American markets, Miacom said.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.